A5075804962- Cholangiocarcinoma and Gallbladder Cancer Studies
- Peptidase Inhibition and Analysis
- Cancer Mechanisms and Therapy
- Cancer Immunotherapy and Biomarkers
- Cell Adhesion Molecules Research
- Cancer, Hypoxia, and Metabolism
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- IgG4-Related and Inflammatory Diseases
- Gastric Cancer Management and Outcomes
- Fibroblast Growth Factor Research
- Neuroblastoma Research and Treatments
- RNA modifications and cancer
- Drug Transport and Resistance Mechanisms
- Protein Degradation and Inhibitors
- Biochemical and Molecular Research
- Cancer Genomics and Diagnostics
- Cancer-related molecular mechanisms research
- Endoplasmic Reticulum Stress and Disease
- Lymphoma Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Immune Cell Function and Interaction
- MicroRNA in disease regulation
Mahidol University
2020-2024
University of Cincinnati Medical Center
2024
University of Cincinnati
2024
University of Nottingham
2024
Ramathibodi Hospital
2020-2022
Siriraj Hospital
2020-2022
Memorial Sloan Kettering Cancer Center
2019
MYC activation is a known hallmark of cancer as it governs the gene targets involved in various facets progression. Of interest, oncometabolism through interactions with its partners and cofactors, well immunity via targets. Recent investigations have taken interest characterizing these multi-Omic approaches, to better understand vastness network. several either or oncoimmunology, few them overlap function. Prominent been observed HIF-1α, promoting glucose glutamine metabolism antigen...
Surgical Patients in tertiary care centers can be healthy or extremely ill with comorbidities, and procedures vary from simple to difficult complicated. High-acuity cases, those involving anesthesia procedural complexities, require specific staff arrangements, nursing team assignments, additional support staff. These cases are identified manually, there is no ready-to-use scoring system stratify high-acuity, complex pediatric surgical patients. We aim develop an electronic medical...
Abstract A poor outcome for cholangiocarcinoma (CCA) patients is still a clinical challenge. CCA typically recognized by the desmoplastic nature, which accounts its malignancy. Among various extracellular matrix proteins, laminin most potent inducer migration. Herein, we accessed expression profiles of gene family and explored significance key subunit on aggressiveness. Of all 11 genes, LAMA3, LAMA5, LAMB3 LAMC2 were concordantly upregulated based analysis multiple public transcriptomic...
Cholangiocarcinoma (CCA) has a complex immune microenvironment architecture, thus possessing challenges in its characterization and treatment. This study aimed to repurpose FDA-approved drugs for cholangiocarcinoma by transcriptomic-driven bioinformatic approach.
Cholangiocarcinoma (CCA) is a difficult-to-treat cancer, with limited therapeutic options and surgery being the only curative treatment. Standard chemotherapy involves gemcitabine-based therapies combined cisplatin, oxaliplatin, capecitabine, or 5-FU dismal prognosis for most patients. Receptor tyrosine kinases (RTKs) are aberrantly expressed in CCAs encompassing potential opportunity. Hence, 112 RTK inhibitors were screened KKU-M213 cells, ceritinib, an approved targeted therapy ALK-fusion...
The potential of members the epidermal growth factor receptor (ErbB) family as drug targets in cholangiocarcinoma (CCA) has not been extensively addressed. Although phase III clinical trials showed no survival benefits erlotinib patients with advanced CCA, outcome standard-of-care chemotherapy treatment for gemcitabine/cisplatin, is discouraging so we determined effect other ErbB inhibitors alone or conjunction CCA cells.ErbB expression was patient tissues by immunohistochemistry and...
Cholangiocarcinoma (CCA) is an architecturally complex tumour with high heterogeneity. Discovery at later stages makes treatment challenging. However, the lack of early detection methodologies and asymptomatic nature CCA make diagnosis more difficult. Recent studies revealed fusions in Fibroblast Growth Factor Receptors (FGFRs), a sub-family RTKs, as promising targets for targeted therapy CCA. Particularly, FGFR2 have been particular interest, translocations found approximately 13% patients....
Cholangiocarcinoma (CCA) is a heterogeneous group of malignancies that primarily originate from the bile duct. Tumor heterogeneity prime characteristic CCA and considering scarcity approved targeted therapy drugs, this makes precision oncology impractical in CCA. Stratifying patients based on their molecular signature biomarker-guided may offer conducive solution. Receptors tyrosine kinases (RTK) are potential targets for novel therapeutic strategies as RTK signaling dysregulated This study...
<title>Abstract</title> Background Neuroblastoma is the most common extracranial solid tumor among pediatric patients, with MYCN amplification marking a significant increase in mortality risk. The utilization of neuroblastoma cell lines serves as first-line model for studying phenotypic outcomes novel therapeutic interventions. Selecting that closely mimic molecular characteristics neuroblastomas derived from patients crucial enhancing efficacy drug discovery. We hypothesized similarity...
Background: Immune evasion in cancer is a multifaceted process that synchronizes pro-tumoral immune infiltration, immunosuppressive inflammation, and inhibitory checkpoint expression (IC). Recent developments have immunotherapies such as blockade (ICB) chimeric antigen receptor T-cell (CAR-T) therapy effectively impede this but benefit limited patient cohort. This investigation introduces systemic immunotherapeutic strategy by inhibition of master-regulators (MR-IE). Methods: We utilized the...
Background: Cancer immune evasion is a multifaceted process that synchronizes pro-tumoral infiltration, immunosuppressive inflammation, and inhibitory checkpoint expression (IC). Current immunotherapies combat this issue by reinstating immunosurveillance of tumors; however, it benefits limited patient population. Thus, more effective immunotherapeutic strategy warranted to cater specific populations. This investigation introduces novel via inhibition master regulators (MR-IE). Methods:...
Introduction Bile duct cancer (cholangiocarcinoma, CCA) has a poor prognosis for patients, and despite recent advances in targeted therapies other types, it is still treated with standard chemotherapy. Anaplastic lymphoma kinase (ALK) been shown to be primary driver of disease progression lung cancer, ALK inhibitors are effective therapeutics aberrant ALK-expressing tumors. Aberrant expression documented CCA, but the use not investigated. Using CCA cell lines close-to-patient...
Cholangiocarcinoma (CCA) is a heterogenous group of malignancies in the bile duct, which proliferates aggressively. CCA highly prevalent Northeastern Thailand wherein it associated with liver fluke infection, or Opisthorchis viverrini (OV). Most patients are diagnosed advanced stages, when cancer has metastasized severely progressed, thereby limiting treatment options. Several studies investigate effect traditional Thai medicinal plants that may be potential therapeutic options combating...
Cholangiocarcinoma (CCA), a devastating epithelial tumor arising in bile ducts with dismal prognosis and high mortality rate, has the highest worldwide incidence Northeastern Thailand, raising serious health public concern to country.Due desmoplastic nature of CCA, understanding CCA cell-matrix interaction is necessitated.Here, an silico analysis using two RNA-sequencing (Pan-Cancer Analysis Whole Genomes The Cancer Genome Atlas) databases ten microarray datasets from Gene Expression Omnibus...
Introduction: Extranodal NK/T cell lymphoma (ENKTL) is a rare subtype of lymphoma, poorly responsive to anthracycline-based chemotherapy. Treatment and prognosis are largely driven by stage, the PINK PINK-E scores appear further refine it. Outcomes for patients with ENKTL have improved L-asparaginase containing regimens into combined modality approaches. Based on reported efficacy SMILE (Yamaguchi, Cancer Sci, 2008), in 2009, we adopted modified (m)SMILE (dexamethasone, methotrexate,...